Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Conor tests dual-drug-eluting coronary stent:

This article was originally published in Clinica

Executive Summary

Conor Medsystems has performed the first patient implant of its dual-drug-eluting coronary stent for preventing restenosis, as a lead-in case to the start of its GENESIS clinical trial. The 375-patient study, which is scheduled to start enrolling patients this summer, is assessing the firm's pimecrolimus/paclitaxel-eluting stent, SymBio. It will also test Conor's investigational pimecrolimus-eluting stent, Corio, and will compare both new devices with the firm's CoStar cobalt chromium paclitaxel-eluting stent, which is already CE-marked for sale in Europe. The SymBio stent capitalises on the advantages of Conor's reservoir-based stent design to deliver more than one drug, said the Menlo Park, California firm. The GENESIS trial is expected to complete patient-enrolment in late 2006 or early 2007.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT051850

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel